INS and metabolic syndrome: Warshauer et al. [22] reported that treatment with pioglitazone, an insulin-sensitizing agent, for 6 months significantly lowered the concentrations of multiple plasma ceramide in 37 subjects with metabolic syndrome, compared to the placebo.